title: Anaphylactoid reaction after verteporfin therapy.
abstract: OBJECTIVE
  To report a case of anaphylactoid reaction in a woman after initial exposure to verteporfin and to alert physicians of this potentially life-threatening reaction.
  
  
  METHODS
  Interventional case report.
  
  
  METHODS
  An 80-year-old woman who was found to have exudative age-related macular degeneration on clinical examination and fluorescein angiography underwent treatment with verteporfin photodynamic therapy (PDT). Thirty minutes after verteporfin PDT infusion, the patient experienced throat constriction, swelling of her hands, and severe shortness of breath. She received immediate intravenous treatment with methylprednisolone, diphenhydramine, and famotidine and was admitted for observation.
  
  
  RESULTS
  The patient's symptoms resolved, and she experienced no long-term side effects related to PDT. Routine noninvasive pulse oximetry, however, did result in finger discoloration and superficial burn. Evaluation revealed that her symptoms were noncardiac in origin.
  
  
  CONCLUSIONS
  Verteporfin can result in an anaphylactoid reaction. Treating physicians should be advised of possible photosensitizing reactions once the patient has received verteporfin PDT.
authors.affiliation: California Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.
authors.forename: Amish B
authors.initials: AB
authors.lastname: Doshi
authors.forename: Darius M
authors.initials: DM
authors.lastname: Moshfeghi
authors.forename: Robert L
authors.initials: RL
authors.lastname: Jack
mesh_terms: D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy; D004155:Diphenhydramine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000009:adverse effects*; D011166:Porphyrins / Q000009:adverse effects*; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D015738:Famotidine; D004155:Diphenhydramine; D008775:Methylprednisolone